Vera Therapeutics won an FDA accelerated approval for Trutakna (atacicept) to treat adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. The agency cleared the dual BAFF/APRIL inhibitor on the July 7 PDUFA date as the first-in-class therapy in this mechanism category. FDA’s decision is based on reduction in proteinuria, with longer-term outcomes expected to be assessed through confirmatory work. Trutakna is administered once weekly via auto-injector. Vera has also positioned confirmatory trial Origin 3 as the path to a potential full approval in 2027, with readouts expected in the third quarter. The accelerated authorization sets up a faster competitive timeline against alternative IgAN strategies already in development.